156 related articles for article (PubMed ID: 31725045)
1. Survival outcomes of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completely resected nonsmall cell lung cancer: FAST-nab.
Marushima H; Kimura H; Miyazawa T; Sakai H; Furuya N; Koji K; Nakamura H; Saji H
Anticancer Drugs; 2020 Feb; 31(2):177-182. PubMed ID: 31725045
[TBL] [Abstract][Full Text] [Related]
2. Feasibility study of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completely resected non-small-cell lung cancer: FAST-nab.
Saji H; Marushima H; Miyazawa T; Sakai H; Kimura H; Kurimoto N; Nakamura H
Anticancer Drugs; 2017 Aug; 28(7):795-800. PubMed ID: 28538017
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: TORG 0503.
Kubota K; Kunitoh H; Seto T; Shimada N; Tsuboi M; Ohhira T; Okamoto H; Masuda N; Maruyama R; Shibuya M; Watanabe K
Lung Cancer; 2020 Mar; 141():32-36. PubMed ID: 31931444
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
Strauss GM; Herndon JE; Maddaus MA; Johnstone DW; Johnson EA; Harpole DH; Gillenwater HH; Watson DM; Sugarbaker DJ; Schilsky RL; Vokes EE; Green MR
J Clin Oncol; 2008 Nov; 26(31):5043-51. PubMed ID: 18809614
[TBL] [Abstract][Full Text] [Related]
5. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.
Chang WJ; Sun JM; Lee JY; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2014 Apr; 84(1):51-5. PubMed ID: 24521819
[TBL] [Abstract][Full Text] [Related]
6. A feasibility study of postoperative adjuvant therapy of carboplatin and weekly paclitaxel for completely resected non-small cell lung cancer.
Yamashita Y; Kataoka K; Ishida T; Matsuura M; Seno N; Mukaida H; Miyahara E; Miyata Y; Okita R; Shimizu K; Watari M; Okumichi T; Okada M
J Thorac Oncol; 2008 Jun; 3(6):612-6. PubMed ID: 18520800
[TBL] [Abstract][Full Text] [Related]
7. A Multicenter Randomized Controlled Study of Paclitaxel plus Carboplatin versus Oral Uracil-Tegafur as the Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer.
Toyooka S; Okumura N; Nakamura H; Nakata M; Yamashita M; Tada H; Kajiwara S; Watanabe N; Okada M; Sakamoto J; Aoe M; Soh J; Miyoshi S; Hotta K; Matsuo K; Date H
J Thorac Oncol; 2018 May; 13(5):699-706. PubMed ID: 29505900
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel and carboplatin adjuvant therapy alone or with radiotherapy for resected nonsmall cell lung carcinoma: a feasibility study of the Minnie Pearl Cancer Research Network.
Greco FA; Burris HA; Gray JR; Raefsky EL; Dobbs C; Smith S; Rinaldi D; Morrissey LH; Erland JB; Litchy S; Hainsworth JD
Cancer; 2001 Oct; 92(8):2142-7. PubMed ID: 11596031
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.
Villaruz LC; Cobo M; Syrigos K; Mavroudis D; Zhang W; Kim JS; Socinski MA
Lung Cancer; 2019 Oct; 136():52-56. PubMed ID: 31445354
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant carboplatin-based chemotherapy in resected stage IIIA-N2 non-small cell lung cancer.
Ou W; Sun HB; Ye X; Zhang BB; Yang H; Fang Q; Li P; Wang SY
J Thorac Oncol; 2010 Jul; 5(7):1033-41. PubMed ID: 20502361
[TBL] [Abstract][Full Text] [Related]
11. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J
J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review.
Custodio Carretero AB; García Sáenz JA; González Larriba JL; Bobokova J; Calles Blanco A; Hernando Trancho F; García Paredes B; Rodríguez Lajusticia L; Díaz-Rubio García E
Clin Transl Oncol; 2008 Sep; 10(9):560-71. PubMed ID: 18796373
[TBL] [Abstract][Full Text] [Related]
13. A pilot study of adjuvant chemotherapy with carboplatin and oral S-1 for patients with completely resected stage II to IIIA non-small cell lung cancer.
Tanaka H; Tabe C; Okumura F; Shiratori T; Ishioka Y; Itoga M; Taima K; Morimoto T; Kimura D; Tsushima T; Tasaka S
Thorac Cancer; 2020 Jun; 11(6):1633-1638. PubMed ID: 32351044
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer.
Feigenberg SJ; Hanlon AL; Langer C; Goldberg M; Nicolaou N; Millenson M; Coia LR; Lanciano R; Movsas B
J Thorac Oncol; 2007 Apr; 2(4):287-92. PubMed ID: 17409799
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
[TBL] [Abstract][Full Text] [Related]
16. Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil-tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial.
Soh J; Toyooka S; Okumura N; Nakamura H; Nakata M; Yamashita M; Sakamoto J; Aoe M; Hotta K; Morita S; Date H
Int J Clin Oncol; 2019 Nov; 24(11):1367-1376. PubMed ID: 31312931
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
Spigel DR; Jotte RM; Aix SP; Gressot L; Morgensztern D; McCleod M; Socinski MA; Daniel D; Juan-Vidal O; Mileham KF; West H; Page R; Reinmuth N; Knoble J; Chen T; Bhore R; Wolfsteiner M; Ong TJ; Gridelli C; Thomas M;
Clin Lung Cancer; 2021 Jan; 22(1):6-15.e4. PubMed ID: 33097414
[TBL] [Abstract][Full Text] [Related]
18. Outcomes in 36 Patients with Stage IIIA-N2 Squamous Cell Carcinoma of the Lung Treated with Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy: A Prospective Study from a Single Center.
Zhu J; Zhang Y; Wang M; Zhang Z; Yue D; Liu S; Pan Y; Wang C
Med Sci Monit; 2021 Aug; 27():e930738. PubMed ID: 34376631
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease.
Kenmotsu H; Yoh K; Mori K; Ono A; Baba T; Fujiwara Y; Yamaguchi O; Ko R; Okamoto H; Yamamoto N; Ninomiya T; Ogura T; Kato T
Cancer Sci; 2019 Dec; 110(12):3738-3745. PubMed ID: 31608537
[TBL] [Abstract][Full Text] [Related]
20. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
Miyauchi E; Inoue A; Usui K; Sugawara S; Maemondo M; Saito H; Fujita Y; Kato T; Suzuki T; Harada T; Watanabe H; Nakagawa T; Ichinose M
Oncologist; 2017 Jun; 22(6):640-e59. PubMed ID: 28526722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
